Radioimmunotherapy (RIT) Dose-Escalation Studies in Prostate Cancer Using Anti-Psma Antibody 177Lu-J591: RIT Alone and RIT in Combination With Docetaxel

doi 10.21236/ada512754

Full Text

Abstract

Available in

Date

Authors

Publisher

Defense Technical Information Center

Related search

Theranostic Radioimmunotherapy (RIT) Combined With Immunotherapy: The Best Way to Go?

Medical Research and Innovations
2017English

Double Faced Data Hiding in Images and Videos Using Rit Approach

International Journal of Advance Engineering and Research Development
2017English

Rit GTPase Signaling Promotes Immature Hippocampal Neuronal Survival

Journal of Neuroscience
Neuroscience
2012English

Radioimmunotherapy of Prostate Cancer Using 90y- And 177Lu-Labeled J591 Monoclonal Antibodies: Effect of Multiple Treatments on Myelotoxicity

Clinical Cancer Research
Cancer ResearchOncology
2005English

Radioimmunotherapy for Mantle Cell Lymphoma: 5-Year Follow-Up of 90 Patients From the International RIT Registry

Annals of Hematology
MedicineHematology
2020English

First Experiment of S Π RIT-TPC at SAMURAI in RIKEN-RIBF

2017English

Low-Dose Docetaxel in Combination With Dexamethasone for Hormone-Refractory Prostate Cancer

Japanese Journal of Urology
Urology
2011English

Fully Human IgG and IgM Antibodies Directed Against the Carcinoembryonic Antigen (CEA) Gold 4 Epitope and Designed for Radioimmunotherapy (RIT) of Colorectal Cancers

BMC Cancer
Cancer ResearchOncologyGenetics
2004English

Radioimmunotherapy for Follicular Lymphoma Achieves Excellent Lymphoma Control in First Line and Relapse: 8-Year Follow-Up Data of 281 Patients From the International RIT-registry

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2026 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy